Clinical Takeaway
Trauma-focused treatments for PTSD remain effective even among patients who use cannabis, including those with co-occurring substance use disorders. Cannabis use does not appear to undermine the benefits of evidence-based PTSD interventions, and clinicians should not withhold trauma-focused care from patients on this basis.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis addresses a critical clinical gap by evaluating whether evidence-based trauma-focused treatments maintain efficacy in patients with comorbid PTSD and substance use disorders who actively use cannabis, a population frequently excluded from or underrepresented in treatment trials. The findings directly inform clinical decision-making regarding treatment selection and patient expectations for individuals with this highly prevalent and challenging comorbidity. Understanding treatment outcomes in active cannabis users has substantial implications for treatment planning, as it determines whether clinicians should modify standard protocols or maintain fidelity to established evidence-based approaches.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 This meta-analysis raises an important clinical question about whether cannabis use compromises outcomes in trauma-focused psychotherapy for patients with co-occurring PTSD and substance use disorders, though several limitations warrant careful interpretation. The analysis draws from Project Harmony’s larger evidence base but examines only a subset of four RCTs, which restricts generalizability and statistical power to detect meaningful treatment interactions. Cannabis use patterns are heterogeneous in terms of frequency, potency, and concurrent use with other substances, yet most studies treat cannabis as a binary variable, potentially obscuring whether occasional versus heavy use differentially affects treatment response. Additionally, the underlying question of whether cannabis use impairs therapy outcomes or whether cannabis users represent a distinct population with greater baseline severity or lower treatment engagement remains incompletely disentangled. Clinically, while we await more robust prospective data specifically designed to answer this question, current evidence suggests that cannabis use alone should not categorically exclude patients from evidence-based trauma-focused treatment, though informed discussion about potential interactions between active cannabis